학술논문
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.
Document Type
article
Author
Tarke, Alison; Sidney, John; Methot, Nils; Yu, Esther Dawen; Zhang, Yun; Dan, Jennifer M; Goodwin, Benjamin; Rubiro, Paul; Sutherland, Aaron; Wang, Eric; Frazier, April; Ramirez, Sydney I; Rawlings, Stephen A; Smith, Davey M; da Silva Antunes, Ricardo; Peters, Bjoern; Scheuermann, Richard H; Weiskopf, Daniela; Crotty, Shane; Grifoni, Alba; Sette, Alessandro
Source
Cell reports. Medicine. 2(7)
Subject
Language
Abstract
The emergence of SARS-CoV-2 variants with evidence of antibody escape highlight the importance of addressing whether the total CD4+ and CD8+ T cell recognition is also affected. Here, we compare SARS-CoV-2-specific CD4+ and CD8+ T cells against the B.1.1.7, B.1.351, P.1, and CAL.20C lineages in COVID-19 convalescents and in recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines. The total reactivity against SARS-CoV-2 variants is similar in terms of magnitude and frequency of response, with decreases in the 10%-22% range observed in some assay/VOC combinations. A total of 7% and 3% of previously identified CD4+ and CD8+ T cell epitopes, respectively, are affected by mutations in the various VOCs. Thus, the SARS-CoV-2 variants analyzed here do not significantly disrupt the total SARS-CoV-2 T cell reactivity; however, the decreases observed highlight the importance for active monitoring of T cell reactivity in the context of SARS-CoV-2 evolution.